Medical Therapeutics and Health Challenges
Basics of Medicines
Before therapy, vocabulary. Two distinctions trip up beginners and delight examiners. First — is every drug a medicine? No. A drug is any chemical that affects body function (including morphine and nicotine); a medicine is the narrower set of drugs used specifically to diagnose, treat or prevent disease.
Every medicine is a drug; not every drug is a medicine.
Drug vs Medicine
| Feature | Drug | Medicine |
| Definition | Any chemical that affects body function | A drug used for diagnosis, treatment or prevention |
| Scope | Broad (beneficial AND harmful) | Narrow (therapeutic only) |
| Purpose | May or may not treat | Specifically for medical purposes |
| Safety | Can be harmful/addictive | Intended to be safe when used properly |
| Usage | Medical and non-medical (e.g., narcotics) | Strictly medical/clinical |
| Example | Morphine, nicotine | Paracetamol, antibiotics |
The second distinction — generic vs branded. The secret most people don’t know: the active ingredient is identical. ‘Crocin’ is just paracetamol with a brand name and marketing. Same molecule, same efficacy — only the price and packaging differ. This single fact underpins India’s entire affordable-medicine policy (think Jan Aushadhi).
Generic vs Branded Medicines
| Feature | Generic | Branded |
| Sold under | Chemical (non-proprietary) name | Brand name given by a company |
| Active ingredient | Same as branded | Same as generic |
| Effectiveness | Same efficacy & safety | Same efficacy & safety |
| Cost | Cheaper | Costlier |
| Marketing | Minimal/none | Heavy promotion |
| Example | Paracetamol | Crocin (brand of paracetamol) |
Antibiotics, Antivirals & Antifungals
These three are the foot-soldiers against communicable disease, and the single most common exam error is mixing up what each one targets. The mantra: antibiotics for bacteria, antivirals for viruses, antifungals for fungi. This is why taking an antibiotic for a viral cold is useless — and, as we will see, actively dangerous.
| Feature | Antibiotics | Antivirals | Antifungals |
| Target | Bacteria | Viruses | Fungi |
| Function | Kill/inhibit bacteria | Inhibit viral replication | Kill/inhibit fungi |
| Cell type | Prokaryotic cells | Viruses (non-cellular) | Eukaryotic fungal cells |
| Mode of action | Disrupt cell wall, protein synthesis, DNA | Block viral entry/replication/assembly | Disrupt fungal membrane/wall |
| Example diseases | TB, pneumonia, cholera | Influenza, COVID-19, HIV | Ringworm, candidiasis |
| Example drugs | Penicillin, Amoxicillin | Acyclovir, Remdesivir | Fluconazole, Amphotericin B |
| Resistance issue | High (antibiotic resistance) | Moderate | Increasing concern |
Emerging Health Issues
Antimicrobial Resistance (AMR) — the Silent Pandemic
AMR is when microorganisms change over time and stop responding to the drugs designed to kill them. The germ evolves; the medicine fails. When a microbe defeats multiple drugs at once, we call it a superbug — extremely hard, sometimes impossible, to treat.
Here is the crucial conceptual point that examiners test: resistance develops in the microbe, not in the human. Your body does not become resistant; the bacteria do, by mutation and natural selection.
Every time we misuse an antibiotic, we kill the weak bacteria and leave the strong, resistant ones to multiply. We are, in effect, breeding our own enemies.
| Antibiotic misuse kills the WEAK bacteria |
| ▼ |
| The few naturally RESISTANT bacteria survive |
| ▼ |
| They multiply, passing resistance genes on |
| ▼ |
| Soon the whole population is resistant → a ‘superbug’ |
Causes of AMR
- Overuse & misuse of antibiotics: taking them for viral colds/flu (where they do nothing), broad-spectrum overuse, self-medication without prescription.
- Incomplete treatment: not finishing the full course lets the toughest microbes survive and adapt.
- Overuse in agriculture & animal husbandry: antibiotics for livestock growth → resistant bacteria reach humans via food, water, contact.
- Poor infection control, lack of new antibiotics (pharma invests less — low profit), environmental contamination (antibiotic residues in effluents), and natural evolution (mutation, gene exchange).
Consequences of AMR
- Increased morbidity & mortality: once-treatable infections turn deadly — AMR causes over 1.2 million deaths globally each year.
- Higher healthcare costs, jeopardised medical procedures (surgery, chemotherapy, transplants all rely on working antibiotics), global spread (pathogens cross borders), and threats to food security.
Examples of AMR — by microbe type
| Type | Example | Resistant Concern |
| Bacteria | MRSA | Resistant skin, lung, bloodstream infections |
| Bacteria | MDR-TB & XDR-TB | TB resistant to first- & second-line drugs |
| Bacteria | CRE | Gut bacteria resistant to last-resort antibiotics |
| Bacteria | Drug-resistant Gonorrhoea | Nearly untreatable by standard antibiotics |
| Virus | HIV | Resistance to certain antiretrovirals (ARVs) |
| Virus | Influenza | Resistance to amantadine, rimantadine |
| Fungus | Candida auris | Multi-drug resistant, often hospital-acquired |
| Parasite | Plasmodium falciparum | Emerging artemisinin resistance (malaria) |
Strategies to Tackle AMR
The response is global and coordinated, built on the powerful idea that human, animal and environmental health are one — the One Health approach.
- Global Action Plan on AMR (WHO, 2015): the global blueprint, with five objectives — improve awareness, strengthen surveillance, reduce infection, optimise antimicrobial use, and invest in new medicines/diagnostics/vaccines.
- Key programmes: GLASS (Global AMR Surveillance System); the AWaRe classification (Access, Watch, Reserve groups of antibiotics); the One Health approach (WHO + FAO + WOAH); WASH initiatives; and Infection Prevention & Control (IPC) programmes.
India’s Steps Against AMR
- National Action Plan on AMR (NAP-AMR, 2017–2021): aligned with the WHO plan and the One Health approach; six priorities — awareness, surveillance, IPC, optimise use, promote research, and strengthen India’s leadership.
- Red Line Campaign (MoHFW, 2016): a public-awareness drive — medicines marked with a red vertical line (including antibiotics) must not be taken without a doctor’s prescription.
- Schedule H1 Drugs (under Drugs & Cosmetics Rules, 1945; effective 2014): a legal category for high-misuse drugs (3rd/4th-gen antibiotics, anti-TB, anti-retrovirals). Mandatory red stripe + ‘Rx’, sale only on valid prescription, and pharmacists must keep records for 3 years.
Note the key difference: the Red Line Campaign is awareness (voluntary); Schedule H1 is law (enforced). One changes behaviour, the other changes the rules.
| Aspect | Schedule H1 | Red Line Campaign |
| Launched | GoI, 2014 | MoHFW, 2016 |
| Type | Legal classification (D&C Rules, 1945) | Behaviour-change communication |
| Target | Pharmacists, doctors, manufacturers | General public |
| Sales regulation | Valid prescription; 3-year record | No legal restriction |
| Enforcement | Monitored by Drug Control Authorities | Voluntary (awareness only) |
Disease X — Preparing for the Unknown
A fascinating, almost philosophical idea. Disease X is a hypothetical term coined by WHO for an unknown pathogen that could cause a serious future epidemic. It is not a real disease — it is a placeholder for the next pandemic we cannot yet name.
In 2018, WHO added it to its priority-diseases list (alongside Ebola, Zika, SARS) precisely to force the world to prepare for the unexpected. COVID-19, in hindsight, was a ‘Disease X’ that came true.
- Possible candidates: new zoonotic viruses (the likeliest — ~75% of emerging diseases are zoonotic); mutated viruses (e.g., novel flu strains); drug-resistant superbugs; latent viruses released from thawing permafrost; and synthetic/engineered pathogens.
- Why it matters: it pushes preparedness — broad-spectrum antivirals, adaptable vaccine platforms (like mRNA), rapid diagnostics; promotes the One Health approach; and strengthens global surveillance and political awareness of health security.
Advanced Medical Interventions — Organ Transplantation
Now to one of medicine’s most dramatic achievements. Organ transplantation moves a healthy organ or tissue from a donor to a recipient whose own organ has failed, to restore normal function. Commonly transplanted: solid organs (kidney, liver, heart, lungs), tissues (cornea, skin, bone, heart valves), and blood/stem cells (bone marrow).
Types — by Genetic Relationship
The single biggest factor deciding success is how genetically close donor and recipient are, because that decides the risk of immune rejection. The closer the match, the less the body fights the new organ. Four types, from closest to most distant:
| Type | Donor → Recipient | Rejection Risk | Example |
| Autograft | Same individual (self) | None | Skin graft; coronary bypass with own vessels |
| Isograft | Identical twins | Minimal | Kidney between identical twins |
| Allograft | Same species, genetically different | Risk → needs lifelong immunosuppression | Most human transplants (kidney, liver, heart) |
| Xenograft | Different species | Very high | Pig heart valve into a human |
| The trade-off that runs through transplantation There is a cruel logic here. The safest transplant (autograft) is the most limited — you only have so much of your own tissue. The most useful (allograft) carries rejection risk and demands lifelong immunosuppressive drugs, which themselves raise infection risk. And the one that could end the organ shortage forever (xenograft, from animals) carries the highest rejection and zoonotic risk of all. Every gain in availability costs something in safety. That tension is the whole story of modern transplantation. |
Types — by What is Transplanted & by Donor
- By organ/tissue: organ transplant (solid organs — life-saving but major surgery + immunosuppression); tissue transplant (cornea, skin, bone — lower rejection, storable); cellular transplant (bone marrow, islets — treats blood cancers); blood transfusion (the most common transplant); and synthetic organ transplant (3D-printed/bioengineered organs — could end donor shortage but still experimental).
- By donor type: living donor (immediately available, better planning, but surgical risk to donor) vs deceased donor (expands availability but limited by retrieval time, viability and long waiting lists).
THOTA, 1994 — the Law Governing Transplants
India regulates all this through the Transplantation of Human Organs and Tissues Act (THOTA), 1994 (amended 2011), whose twin goals are to enable therapeutic transplantation and to prevent the commercial exploitation of the poor.
- Legal recognition of brain-stem death — this is what makes deceased donation possible.
- Living donors mainly from near relatives (with written consent); unrelated donation only with Authorisation Committee approval.
- Swap transplantation allowed between near-relative pairs who are mutually incompatible (after committee approval, no money).
- Prohibition of organ trade (imprisonment + fines); Authorisation Committees to prevent trafficking; and registration of hospitals/tissue banks.
Key Institutions & Days
- NOTTO (National Organ & Tissue Transplant Organisation) — apex body under MoH&FW, at Safdarjung Hospital, Delhi. ROTTOs (5 regional bodies — Chennai, Kolkata, Mumbai, Chandigarh, Guwahati) and SOTTOs (state level).
- World Organ Donation Day — August 13; Indian Organ Donation Day — August 3 (marks India’s first successful deceased-donor heart transplant, 1994).
Challenges of Organ Donation in India
- Awareness & cultural barriers (myths, body-integrity beliefs); very low cadaveric donation rate — under 1 per million vs 25–30 in Spain/USA; heavy reliance on living donors.
- Infrastructural gaps, legal/regulatory hurdles, organ-trafficking & transparency issues, financial barriers, ethical concerns, and logistical challenges. A green corridor — a special traffic-cleared route — is used to rush a harvested organ from donor to recipient hospital.
Xenotransplantation — Borrowing Organs from Animals
The boldest answer to the organ shortage. Xenotransplantation is the transplant of live cells, tissues or organs from one species to another — most often from pigs to humans. It is still experimental, not standard care.
| Why pigs, of all animals? It seems strange until you see the logic. Pig organs are similar in size, structure and physiology to human organs. Pigs reproduce quickly and in large numbers (a steady supply). They can be genetically modified to reduce rejection. And — crucially — they pose a lower zoonotic risk than our closer cousins, the non-human primates. Size, supply, modifiability, safety: the pig wins on all four. |
- Types: cell (pig islet cells for diabetes — experimental); tissue (pig heart valves — already common); whole organ (pig heart/kidney into humans — experimental).
- Advantages: addresses the organ shortage with a readily available supply; ‘bridge transplants’ to sustain patients; treats specific diseases (Type-1 diabetes); boosts biomedical research; advances with CRISPR/genetic engineering.
- Challenges: extremely high immune rejection (hyperacute/acute/chronic); cross-species zoonotic infection (e.g., porcine retroviruses); ethical/societal/religious concerns; limited long-term data; high cost; heavy immunosuppression burden; and evolving regulatory frameworks.